Paying participants for the essential role that they play in clinical trials is important, but the amount given, and how it is paid, require careful consideration. Appropriately compensating clinical trial participants lessens the financial burden placed on them by participa … Read More »

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic … Read More »

If identifying and including patients is one of the biggest hurdles of a clinical trial, how does access to 100 million patients sound? This white paper shares how a robust patient database is one critical key that impacts multiple facets of a trial, leading to more successf … Read More »

The biggest challenge facing clinical research today is the need to gather, analyze, and report data. To collect patient data more efficiently, the industry has turned to electronic patient-reported outcome (ePRO) tools, which allow patients to enter data themselves, most of … Read More »

Since the end of the pharmaceutical industry’s “blockbuster era” and the beginning of its “specialty product era”, drug makers have used the term “hub services” to describe the often ponderous process of  ranting patients access to critical medications. While the term itself … Read More »

Discover what you can do today to firmly establish your competitive advantage – to avoid being relegated to the sidelines. Will 2021 allow us to bid farewell to COVID-19? Whether we can eradicate this terrible virus or not, many of its impacts will persist. To assist Sponsor … Read More »

Targeted expertise when and where you need it: WCG Clinical Research Coordinators help equip sites to navigate the “new normal.”

As the market landscape relative to co-pay assistance programs continues to evolve, it is important for biopharmaceutical manufacturers to have a practical strategy in place.  This white paper provides valuable insight into planning for 2021 and beyond. TrialCard Incorporate … Read More »

The defining medium of our age, social media has revolutionized the way we communicate, learn about the world, and organize ourselves into communities. For doctors and other HCPs, social media presents an unprecedented opportunity for engagement and collaboration that is sha … Read More »

A deer in the headlights. That’s an easy way to describe most sales leaders right now, as they formulate how they’re going to implement new “virtual selling” sales frameworks with their formerly “press the flesh” sales teams. But really – a year ago – if you’d suggested to m … Read More »

As COVID-19 continues to disrupt clinical research, the consequences are poised to be devastating for sponsors, physicians, patients, and worldwide health. Elligo Health Research® is uniquely situated and experienced to support the continuation of effective clinical research … Read More »

The disconnect between clinical research and medical care has become increasingly burdensome, especially in the wake of the COVID-19 pandemic. As clinical research sponsors continually seek ways to accelerate their trials while maintaining safety and quality, technology rema … Read More »

Infectious disease “challenge” studies, in which healthy participants are deliberately infected with pathogens to investigate the cause, prevention, and treatment of infectious diseases, hold great potential for delivering high-quality data about new interventions. Infectiou … Read More »

Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. The biggest challenge facing clinical research today is the need to gather, analyze, and report data. To collect patient data more efficiently, researchers are increasingly explorin … Read More »

Affordability programs, like co-pay programs, are highly effective at helping patients initiate therapy by reducing cost barriers. While they also improve fill rates incrementally, affordability programs only address the financial barriers to non-adherence without tackling t … Read More »

Susan  Abedi shares how AI can be a positive disruptor for diagnosis – how to take advantage of  its potential and engage effectively with HCPs and patients to shorten the time to diagnosis. She also covers how AI can raise awareness of the clinical journey. There is also a … Read More »

The world of medical claims data can be extremely complex. With over 100,000 ICD-10 diagnosis and CPT procedure codes currently in use, to wade through de-identified claims data often rests solely on the expertise of those who can confidently navigate vast amounts of big dat … Read More »

View this informative infographic containing numerous statistics about influenza in the U.S.

To help you manage effectively through the intricacies of 340B, Manatt Health has developed a 50-state survey on 340B, analyzing how states reimburse 340B covered entities and contract pharmacies for 340B drugs, and the steps states are taking to avoid duplicate discounts. D … Read More »

“Behavioral science” is becoming a buzzword for pharma. Why? Because behavior is a barrier to meeting brand objectives. This barrier could be in the form of a patient’s adherence, a patient’s reluctance to start a new therapy, or even a healthcare provider’s clinical inertia … Read More »

This white paper provides critical information about obstacles to continued oncology research and recommendations for effectively overcoming them. It first traces current and projected trends in the field of oncology and related market research. Next it presents key findings … Read More »

Data from clinical trials is extremely valuable but often underutilized. This is typically the result of insufficient planning. Industry experts are frustrated knowing that stakeholders do not have sufficient access to their data, thus losing tremendous value since the data … Read More »

Storytelling may seem like an antiquated tool in modern times, which is exactly what makes it so powerful. How? Life unfolds in the narratives we share with each other. A great story can go where quantitative analysis often cannot: straight to the heart. Clinical trial data … Read More »

This white paper explores how some of the world’s most innovative companies are bringing the patient experience front and centre in clinical trials, and reaping the benefits of doing so. From protocol design to recruitment and retention, it’s about seeing every touchpoint th … Read More »

In revolutions past, there have been moments when a seemingly singular entity or action emerges spontaneously and changes the existing course of action. But more often, it is multiple factors that coincide and work in tandem to comprehensively transform an entire industry or … Read More »

Sharp rises in opioid abuse and overdose rates in the United States over the past two decades have prompted much-needed review of prescription rates and ease of access to controlled substances.  Combatting these alarming trends requires assessing which opioids are more addic … Read More »

Over the years, studies have been conducted to ascertain the cost of research and development (“R&D”) required to bring a new drug to market. Experts disagree on the exact amount, but the consensus is that the figure is in the hundreds of millions to over a billion dolla … Read More »

The therapeutic landscape is shifting rapidly, and it’s becoming more and more important for those involved in overseeing clinical research to be familiar with the latest breakthroughs and treatments. Increasing sophistication in the design, conduct, and analysis of clinical … Read More »

Investigative site payments have long been recognized as a major pain point along the drug development continuum. Too often, the processes by which payments to sites by contract research organizations (CROs) and Sponsors are made are complicated, burdensome, time-consuming, … Read More »

This white paper describes how standardized performance metrics designed to measure various sub-steps help to optimize the SSU process by providing transparency into the following bottlenecks that could derail study activation, cycle times and budgets: • Contract negotiation … Read More »

Virtual engagement strategies are evolving the way the pharmaceutical industry connects with key stakeholders. By using a blend of technology and experienced personnel to seamlessly connect brands to healthcare professionals, virtual engagement offers a solution to the trend … Read More »

Neither orphan drug manufacturers nor their patients with rare diseases are served well by the traditional multi-channel model of drug delivery and patient service. A new integrated model increases adherence and improves patient outcomes, which in turn leads to better financ … Read More »

No group of stakeholders wields greater influence over patient access to medicines than payers making reimbursement and formulary decisions. Even in a time of policy upheaval in Washington, health plans must make sure members get the medicines they need. Insurers say they’re … Read More »

Life science companies are experiencing a significant transformation in how they bring new products to market. Organizations must adapt to changes in the marketplace, such as global product commercialization, specialized medicine, new regulations, new payment models, and new … Read More »

For patients with serious and rare diseases, time is of the essence, and the traditional drug development process may take far too long. To speed innovative new drugs to market, the FDA has established four expedited programs that allow the development process to be compress … Read More »

Mobile apps are an important link between researchers and patients, but using them in clinical development requires rigorous preparation. Download this white paper to learn more about data strategies for mobile apps throughout the trial life cycle, the current and future reg … Read More »

Smaller companies have unique needs in regards to clinical trials. Historically, vendors have approached the clinical trials industry with a “one size fits all” technology approach that is too big, expensive and cumbersome to maintain, or provides little actual value for wha … Read More »

In our ever-more patient-centric world, a key question arises – what do patients think about DTC? Health Perspectives Group, experts in patient engagement since 2002, partnered with eyeforpharma to answer this question in today’s changing environment. They contacted the Food … Read More »

In this white paper, we’ll discuss the guidances compelling organizations to compile data into standardized, digital datasets, the FDA’s motivation behind these changes and the benefits to — as well as the hopes of — the organizations that must submit standardized data. Ther … Read More »

Today’s consumers have choices about how and where they gather pertinent health information, and conversely, pharmaceutical companies have endless options on how, when and where to reach them. The plethora of options introduces a new quandary—where to begin? This white paper … Read More »

Through sustained partnerships between advocacy and industry, the US and Europe can overcome barriers to care. As a source of human suffering, a barrier to workplace productivity, a burden on families and a driver of medical costs, mental illness amounts to an unparalleled p … Read More »

A stand-out digital solution is one that is highly valued by the patient, seamlessly integrated, and delivers measurable results, such as improved health outcomes. Learn about an established process and infrastructure to design, implement and measure digital tools. Increasin … Read More »

While development of promising new products is an obvious area of focus for biopharmaceutical companies, maintenance of already established marketed products is a critical activity that cannot be ignored. As products mature, there is high pressure to grow or sustain revenue … Read More »

GSK’s move to a new model of customer engagement has generated a great deal of debate. Indeed, many commentators remain skeptical that this ‘ethical’ model – especially the decoupling of sales incentives from prescription volume isn’t robust enough to deliver results in the … Read More »

The self-management challenges for people living with chronic conditions are broad and are influenced by a range of factors, both internal and external to the individual. This report outlines how when designing support systems and programs to aid self-management, it is impor … Read More »

To manage chronic medical conditions, real-time monitoring of disease-specific physiologic metrics is becoming an important part of standard of care, and smartphone technology is making it possible. Existing smartphone interfacing devices now record health parameters and met … Read More »

The rise of generic medicines, regulatory pressure, and rampant consumer adoption of technology demands that the life sciences industry adopt a more direct and value-driven engagement to remain competitive. Harnessing digital technology allows you to meet these new industry … Read More »

While the Affordable Care Act continues to be politically polarizing, stakeholders from across the health reform landscape are focused on effectively implementing the law and on making incremental – not radical – changes to it. The question is how such change might happen gi … Read More »

Regulatory scrutiny in clinical research has intensified in recent years, and there are no signs that the intensity of the regulatory environment is abating. In the context of increased outsourcing of clinical study activity to CROs, inspectors are showing an increased inter … Read More »

Findings reveal that based on the industry’s current level of participation in social media, utilization of technology, and effectiveness of social programs, the pharma industry is in the early stages of social media maturity. In fact, only 13% of those that participated in … Read More »

An estimated 400 million people worldwide are currently living with rare diseases. There are approximately 7,000 different types of rare diseases and disorders, with more being discovered every day. At best, the knowledge base about any individual rare disease is small, frag … Read More »

Managing an efficient, well-organized start-up phase is critical to overall study success. While IRB review is just one element of the study start-up process, the IRB can play a crucial role in reaching key study milestones in multisite clinical trials for sponsors, CROs and … Read More »

If you have ever worked with Orphan Drugs, you know finding appropriate patients is a major commercial challenge. Pharmaceutical sponsors of Orphan Drugs often lack the infrastructure and capabilities necessary to identify physicians who diagnose, treat, and manage these rar … Read More »

Do men and women trust the biopharmaceutical industry? How do the genders agree and disagree on this topic?  The results of two recent surveys paint a concerning picture, yet also show ways the industry can impact these opinions. This analysis reveals how men and women prefe … Read More »

Research shows that data errors—missed adverse events, data anomalies and procedural deviations— can lead to costly study delays. Data errors are harder to spot as trials become more complex, which means standard practices for evaluating protocols and clinical data need to i … Read More »

Clinical investigators rely on you to provide timely and accurate reimbursements. But it’s not always easy to keep up. Simplify the process using your existing EDC system, which already stores the data you need to set up and calculate site payments. Turn your traditional EDC … Read More »

Together, technological advancements and tectonic shifts in the healthcare delivery model are pushing us toward an emerging health economy in which pharma marketers increasingly focus their efforts on each patient as a “Segment of One.” In this new segment-of-one model, busi … Read More »

Those who run co-pay programs often see them as absolute–something they employ as part of their strategy, and from which the impact is easily understood. The reality is, however, that co-pay programs work to varying degrees. Simply having one will attract more patients, but … Read More »

Leveraging clinical trial data to decrease risk, time, and cost. Clinical trial data is critical to bring new treatments to market quickly and in a cost-effective manner. Clinical trial data is the most valuable asset for life sciences companies. However, companies struggle … Read More »

There are three valuable benefits of using behavioral insights when planning a marketing program. First, they provide validated models for better predicting human behavior, as opposed to personal opinions or guesswork. Second, they reveal how non-rational and non-conscious f … Read More »

Taken together, rare diseases afflict as many as 30 million Americans, nearly 10% of the US population. To date, as many as 8,000 rare diseases have been identified, but only 5% of rare diseases currently have any FDA-approved drug treatment. The orphan drug marketplace cont … Read More »

This report is a summary of findings from Cello Health Insight’s 2015 research survey of doctors across eight markets; including the UK, France, Germany, Italy, Spain, the US, China and Brazil. The research explores the ways in which doctors are interacting with digital comm … Read More »

Companies like Turing Pharmaceuticals and KV Pharmaceuticals have grabbed headlines recently for their aggressive pharmaceutical pricing strategies. Whether these strategies are justified or even successful is not the point. Rather, what is important is the negative public p … Read More »

Clinical Ink surveyed 500+ research coordinators and investigators to reveal that eSource is faster and easier for sites to use than paper source. Learn how eSource can improve clinical trial efficiency and data quality by reducing more than 50% of site workload.

What are key challenges with treatment adherence among rare disease patients and how can we improve self-management of their condition? In a recent White Paper, Atlantis Healthcare examines the complex landscape of rare disease and addresses how health psychology frameworks … Read More »

Biological medicines have made substantial contributions to the treatment of many chronic and serious diseases and are expected to provide significant therapeutic benefits to many patients who would otherwise have had limited treatment options. Increasingly aging populations … Read More »

Electronic Data Capture (EDC) has become an increasingly popular solution for streamlining data processing. A potential steep learning curve for clinical research teams, structural changes in organizations, and perceived high cost of EDC implementation are some of the legiti … Read More »

This analysis of real-world examples and research shows the relationship between emotional connections, shared values and consumer behavior and discusses four ways biopharma companies can apply these elements to build brand loyalty. There is also a related podcast on this to … Read More »

As the healthcare landscape moves increasingly toward outcome-based treatment approaches, the need to gather and analyze real-world outcome data has become paramount to gauging medication effectiveness and subsequently recruiting prescribers as brand advocates. This study ou … Read More »

The healthcare industry has been wringing its collective hands for years about the problems surrounding “patient engagement.” Beyond the fact that no one has a really good definition of what constitutes patient engagement, most everyone agrees that if you have more patient e … Read More »

Oral treatments are transforming cancer care, moving the administration of treatment from the hospital to the patient’s home. This is shifting the responsibility for managing medications from healthcare professionals to patients, making adherence an important consideration i … Read More »

A White Paper discussing the benefits and key considerations behind implementing a mobile strategy for patient data capture in clinical research, as well as analysing how the use of mobile COA solutions (eCOA) can overcome practical challenges of capturing PRO measures throu … Read More »

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more patient-centric models for reporting, analyzing and monitoring of safety data. However, there … Read More »

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we will discuss these five best practices for life science companies to deliver effective multichannel experiences: 1. Ensuring relia … Read More »

Only about 5 percent of those eligible to participate in trials actually do so, even though the number and size of studies have been escalating. Those who do volunteer to participate in trials can face some frustrating experiences, thanks to what could be characterized as a … Read More »

Dramatic changes in U.S. healthcare over the last few years have forced a rethinking of the partnerships pharmaceutical companies form with groups representing patients and families. inVentiv Health Public Relations Group interviewed dozens of patient advocacy organizations … Read More »

Customer-centric ways of engaging HCPs in sales conversations are needed. Tele-sales solutions provide opportunities to develop relationships with HCPs and their offices, and provide solutions that meet their individual needs. Tele-sales solutions are flexible and can be rap … Read More »

Learn how Pharma’s biggest companies are using patient voice data from the social Web to pull valuable, actionable insights to influence business strategy and advance consumer performance. Download the white paper today for in-depth insights.

Testing out new medicines around the world is becoming more complex due to a range of issues ranging from changing import/export regulations, to temperature deviations, to planning uncertainties.  The complexity will only increase as sponsors look to add new sites in new reg … Read More »

Download WEGO Health’s free report on patient research, featuring in-depth- and sometimes surprising insights about patient research on the state of communication between doctors and patients. Hear the Voices of Patient Influencers. How are they changing the healthcare lands … Read More »

How Decisions Will Be Made in Life Sciences 20 Years from Now Today’s business eco-system is complex, and this is especially true for the life sciences industry. Stakeholders include not just the end consumer but those who pay, those who diagnose and those who treat. All the … Read More »

Early drug development requires adherence to Good Manufacturing Practices (GMP) guidelines when manufacturing investigational medicinal products (IMPs) for clinical studies conducted within Europe. IMP manufacturing can be considered an extension of activities of the clinica … Read More »

The pharmaceutical industry has never faced higher financial stakes than it does today, and overcoming modern obstacles requires a contemporary approach that encompasses all aspects of clinical research, pre-market approval, and the market release process. You need a solid m … Read More »

While oral anticancer treatments are convenient for patients, patient adherence to treatment is a significant issue. Patients need support to remain adherent and maximize treatment outcomes. There are many factors that contribute to patient non-adherence to oral anticancer t … Read More »

Healthcare marketers will find that insights from ethnographic research could mean the difference between the success or failure of their efforts to change behavior. Find out more in this informative white paper. There is also a related podcast on ethnography.

Life science companies are effecting a paradigm shift in their focus towards emerging markets driven by the growing economies of these markets and the steady decline of growth opportunities in the developed markets. This paper covers medical communication for emerging market … Read More »

While pharma observers speculate on the death of outdated drug discovery and sales models, some critical wounds to brand marketing have been largely ignored. But in the new multistakeholder-driven environment that requires brands to stay one step ahead, Mark Sales and Fabric … Read More »

Pharma companies seeking to maximize their Return on Investment (ROI) have to accept that their planning must deal with multiple potential futures. The goal is not to predict a single most likely (or hoped for) future. Rather, it is to determine the most probable range of fu … Read More »

Life Science organizations are expanding into new geographical regions to expand business and product longevity. This decentralization can, in many cases, slow down complex processes, reduce operational efficiency and profitability, and delay time-to-market. One such process … Read More »

How does a brand succeed today, while building toward tomorrow? The customer centric evolution is built on data, analytics, customer connectivity, continuous change, and technology. By integrating new intelligence and methodologies to solve today's challenges, a brand c … Read More »

The increased adoption of social media is impacting every industry, but maybe none more than the healthcare industry. Patients and healthcare providers (HCPs) are looking to social media for information and support regarding their health and the health of their patients. Soc … Read More »

In the health and science space specifically, it is now clear that brands increasingly drive decisions from researchers, physicians, payers and consumers. Unfortunately, C-suite science and health executives do not yet seem to realize the significance and potential of that e … Read More »

Drivers of outsourcing and influencers of partner selection vary on the basis of the imperatives and strategy of the sponsor organization and what is desired to be outsourced. This whitepaper outlines three key areas organizations should consider when selecting an outsourcin … Read More »

21st century technologies will create significant opportunities and challenges for all health care stakeholders. Pharmacovigilance too is in transition, with new sources of medical information and methods for its analysis that will transform today's largely reactive sys … Read More »

One of the most critical, yet overlooked, aspects of product success is safe, successful distribution. And for a growing number of pharmaceuticals and biologics, that involves refrigerated, or cold chain, distribution. A problem with your cold chain can quickly become a prob … Read More »

The socialization of the internet has made writing for and reaching a targeted audience not just possible, but necessary. While in the past you may have been successful with taking a broad approach to reaching patients and prospective clients, today user' desires for mo … Read More »

This white paper summarizes insights on compassionate use developed at Siren Interactive's workshop, Critical Issues in Patient Advocacy Engagement & Collaboration: How Do We Find Common Ground?, at the World Orphan Drug Congress in April 2014. Participants included rep … Read More »

Drug makers are just beginning to realize how social networks can improve business results. But what seems like a spoon full of sugar is often a tough pill to swallow when you consider regulatory requirements from agencies like the FDA for use of these networks. Read this pa … Read More »

This white paper explores the current drug development landscape of the pain market and the most promising mechanisms of action in development. It identifies the pain conditions new drugs most commonly targeted for development focus on. Lastly, it covers the commercial impli … Read More »

For the first time in the history of the What Physicians Want! survey of Sermo physicians, a majority of MDs now want “more” or “significantly more” primary care sales representatives calling on them. But that's just the beginning…this report also describes physicians … Read More »

Drug makers are just beginning to realize how collaboration and communication networks can improve business processes. But what seems like a spoon full of sugar is often a tough pill to swallow when you consider regulatory requirements from agencies like the FDA for use of t … Read More »

The small-to-large molecule shift is giving the pre-filled syringe market a shot in the arm, making it one of the fastest growing segments of the injectable drug delivery device market. Pre-filled syringes have become an increasingly important option in the packaging and del … Read More »

“Data”Data” is the most valuable asset in the life sciences industry. Data from multiple trials must be aggregated and delivered in a concise easily understood manner so that decisions can be made and appropriate actions taken. Due to the large volume and complexity of clini … Read More »

Massive data breaches have dominated global headlines in recent months, and security experts predict we will see more this year. Personal data, financial credentials and healthcare records are targets of an evolving breed of cloaked malware wielded by increasingly sophistica … Read More »

Top contact centers utilizing business intelligence to guide the effectiveness of their customer contacts. Analyzing data improves efficiency and effectiveness within a call center. Customer service has become a leading differentiator of contact centers, to the extent that c … Read More »

At the recent 5th annual mHealth Summit in Washington, DC, stakeholders from across the healthcare ecosystem, including patient and caregiver advocates, providers, payers, entrepreneurs, and life sciences companies came together for the inaugural Pharma and Life Sciences Rou … Read More »

Realizing the full potential of a novel injectable drug compound is no small task. In the months and years that lead from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can slow development to a hal … Read More »

Digital signatures complete the quest for paperless automation in a controlled, consistent, and standard manner across any enterprise or ecosystem. This white paper demonstrates how digital signatures improve operational efficiency to reduce product discovery, development, a … Read More »

Using data to produce insights has become a principal priority for the life sciences industry. Yet, improving the processes for managing that data has been problematic. To compete, pharmas must embark on a journey toward analytical maturity.

More than 300 individuals completed the 2013 survey, representing a wide spectrum of investigator jobs and responsibilities, sizes and types of clinical sites in North, South and Central America; Central, Eastern and Western Europe; Asia and Africa. This abstract provides an … Read More »

When a prescription is abandoned, nobody wins. The pharmaceutical brand loses a prescription. The pharmacist loses a customer. The patient loses the clinical benefit of a prescription medication that was prescribed for him/her. To win, pharmaceutical brands, pharmacists, and … Read More »

The PEAK matrix is a framework to assess the relative market success and overall capability of service providers. The 2013 PEAK matrix for Life Sciences ITO is based on 275+ large multi-year life sciences ITO contracts signed by 14 service providers. The only companies rated … Read More »

Based on simulations and projections conducted by multiple groups to date, it is still uncertain who and how many uninsured will, in fact, obtain insurance. Kantar Health undertook an analysis to increase the body of knowledge about the currently uninsured patients. The resu … Read More »

Traditional Application Support & Management (ASM) cannot address the current needs of business. Neither can is proving the high levels of visibility that CIOs need. ASM has arrived at a crossroads. It is time to create a new model where incidents are eliminated, costs are r … Read More »

Looking into the future, proactive safety and risk management will be especially critical as biological advances improve our understanding of disease mechanism and of the effect of medicines on individual patient responses. Therefore, comparative benefit-risk assessment will … Read More »

To ensure that sales teams are adequately equipped for the challenges ahead, ACO and industry thought leaders recommend that account managers possess the seven critical competencies covered in this white paper.

Biotherapeutic development is costly and can take up to 15 years from discovery to market. Companies are turning their attention to the development of biobetters and biosimilars which are perceived to have a lower business risk than developing an originator biologic product.

In this white paper, Gwen Sunderland, Senior Director, Project Management at SynteractHCR, discusses important considerations for the conduct of global clinical trials.

This e-book explores how planning for clinical diagnostic testing with a central lab partner early in clinical protocol development can help optimize clinical trials, drive efficiencies, avoid potential protocol amendments, and minimize costly study delays. Discover the bene … Read More »

The ultimate goal of pharma companies is to bring new treatments to market sooner and address unmet patient needs more quickly. An electronic data management strategy can help sponsors achieve this goal. Sponsors need comprehensive solutions to implement this strategy, and t … Read More »

Manufacturers rely on market research in the form of customized awareness.

The biopharmaceutical sales representative detailing physicians in New York faces a very different environment from his colleagues in London or Tokyo.

This research brief discusses process performance among medical companies (including health care, pharmaceuticals, biotechnology, and life sciences), specifically, by pointing out notable deviations from pan-industry averages.

EVPs, SVPs, VPs and senior directors of targeted life sciences and pharmaceutical companies were surveyed to determine the key challenges and priorities facing finance and accounting (F&A), finance administration and commercial operations. This paper shares the results.

Under the Sunshine Act, the first data submissions reports are due March 31, 2014, and both the life sciences industry and the medical community have significant concerns about the amount of information that must be publicly disclosed. This white paper explores physicians … Read More »

Effective supply planning requires decision making that strikes a balance between what's known and unknown, risk and budget, the needs of the trial and those of patients. The ultimate goal is ensuring that the right patients receive the right drugs at the right time. Ot … Read More »

Using site engagement technology, sponsors are able to take greater control over patient recruitment by ensuring their study is top of mind with global sites. This white paper covers many of the issues related to site engagement, including a pharmaceutical company case study … Read More »

While all leaders are rightly concerned about market share, customer service and returning a profit, they also recognize that sustainable improvements and innovations start with employees who find meaning and satisfaction in their jobs and take pride in their companies. In l … Read More »

Companies preparing to launch their first approved product are faced with the choice of whether

To avoid the constant

A number of factors are leading to a paradigm shift in the way that clinical research is conducted. The increasing cost of research and the adoption of EDC technologies that provide real-time access to data have forced the industry to look at optimized methods of conducting … Read More »

This white paper explains why casting a wide net to gather as many KOLs as possible is an approach that no longer meets business needs. A targeted approach to KOL identification and influence mapping optimizes spend and yields more actionable data faster.

While pharmacovigilance depends extensively on human sources for information input and processing of data, the growing volume of data and evolving regulations necessitates robust technology enabled process execution to manage the myriad of risks. This white paper covers the … Read More »

This white paper discusses how immersive simulations can improve the performance of the entire customer-facing organization, tightening the distribution of performance levels and reducing the variability of quality.

This white paper discusses how innovation will help us deliver on the promise of better medicines to patients sooner and more affordably. But technology and innovation must become flexible in order to do so, and to be flexible they must be extremely intelligent. Artificial i … Read More »

This white paper explores how product lifecycle management (PLM) can enable biopharma companies to develop innovative products that generate real economic benefits for their organizations and health benefits for patients.

There are a number of pitfalls looming for any company that relies on worldwide telephone numbers and IVR platform installations. Global clinical trial, pharma, CRO, Biotech, and life science companies are losing clients and compromising their global clinical trials because … Read More »

ATU studies can be turned into a powerful tactical and strategic tool by making them part of an integrated market research platform that includes a review of competitive promotional strategy, message recall and tracking, longitudinal patient data and prescription analysis, a … Read More »

This whitepaper discusses the changes in Direct to Consumer marketing that are on the horizon. The old model worked for a while, but to thrive in DTC today a more social media marketing approach is needed. The new model is flexible, direct, and can be tracked in real time wi … Read More »

PPD's Cell Based Assay Laboratory was contracted by a client to improve the performance of a potency assay that had been developed for their biological product. The assay met pre-established qualification specifications for linearity, precision, and specificity and has b … Read More »

This white paper provides an overview of the New Challenges for Global Clinical Trials. The specific challenges discussed are the changing regulatory environment, customs requirements, infrastructure issues, data management, regional idosyncrasies, and differing quality stan … Read More »

This white paper provides an overview of what telehealth is, factors driving the healthcare industry to focus on increasing outcomes and reducing costs, how telehealth solutions can enhance health outcomes and reduce costs, benefits life science companies can expect from tel … Read More »

Faced with increased regulation and limited access to physicians, pharmaceutical companies are using analytics to more strategically plan and invest in peer-to-peer programming. Here, Ogilvy Healthworld Marketing Analytics & Consulting investigates the key factors that resul … Read More »

This white paper will address the critical questions for the industry and suggest prospective approaches that the industry can leverage as progressive companies target the enormous global emerging market that is older adults.

Economic challenges have increased the need for pharmaceutical companies to streamline their approach to selling their products. Among the alternatives, e-promotion provides a cost-effective means to promote brand awareness. Encuity's eAnswers Annual Study provides a com … Read More »

This is a placeholder white paper. We are testing the new feature that allows us to specify any url as related content.

This white paper explores the value personalized medicine holds in predicting risk and providing prognostic indicators, an overview of how personalized medicine has been applied to oncology treatment, and insights into challenges in commercializing personalized medicine appr … Read More »

The innovative approaches described in this paper include finding unique ways to bring stakeholders together to interact and engage in revealing dialogs. Using these market research techniques, marketers will discover new ways to affect behavior, overcome barriers to adoptio … Read More »

In today's business climate, the pharma marketer's paramount focus is targeting. The need to justify every dollar spent to drive bottom-line results is at an all-time high, with the digital channel making this mission both complex and easy. Complex because the audi … Read More »

Several high-profile safety issues, regulatory warnings and negative media coverage have sent ripples through the PV pond that will forever change pharmacovigilance as we know it today. This white paper offers a strategic framework for PV decision makers to more effectively … Read More »

This white paper covers causes of the gender gap in business, details and results of a successful a pilot program, and how external coaching can improve women's careers.

This white paper covers how persistent virtual environments empower new forms of communication and collaboration for business of all sizes.

Accountable Care Organizations (ACOs) take a different approach to defining what medical problems they aim to solve for their patients—as well as how they intend to solve them. Pharma may want to rethink its own role in providing—and positioning—the solutions it offers … Read More »

The interaction between the prescriber and patient is the last-moment opportunity for a brand to express its therapeutic value—having your brand present at the point-of-prescription provides payoff for all other tactics in your marketing mix. Brand managers who keep this i … Read More »

This white paper talks about the need for Global Biosimilar Programmes.

This white paper covers the responsibilities of the pharmaceutical company for regulatory issues, including those related to it outsourcing partners. Learn from interviews with Regulatory Operations executives from five of the top 10 pharma companies.

This white paper gives an overview of the role of observational research in the pharmaceutical industry.

This white paper covers numerous issues related to noncompliance, and what it means to sponsor companies. It describes how patient support programs can make a significant difference in patient behavior, resulting in higher patient compliance rates, better patient health, low … Read More »

This white paper discusses Russia joining the global economy and the burgeoning new pharma market there.

This white paper discusses how the efficiency with which investigator sites enroll patients is still one of the most critical drivers of timely trial completion.

This white paper provides extensive information on how regional marketing is now an essential element of the marketing mix, resulting in increased return on investment for many brands. Covers healthcare reform issues and the new commercial model.

This white paper illustrates how tele-sales solutions provide valuable interactions and develop relationships with healthcare providers and their offices in customized ways that meet their individual needs.

This whitepaper discusses drug-induced liver injuries within pharmaceutical development.

This whitepaper discusses using adaptive social media in the pharmaceutical industry.

It may come as a surprise to many pharmaceutical industry experts that the largest portion of an R&D sponsor's investment and the biggest driver of trial budgets is patient enrollment at 32% of trial costs . To those who are already aware of this, it may still be surpri … Read More »

A large pharmaceutical company faced a serious potential problem with FCPA compliance and partner due diligence processes. Through creation of a rigorous best practice FCPA program, the company was able to significantly mitigate their exposure through execution of an enhance … Read More »

As the pace and scope of change within the healthcare life sciences continue to increase, many are questioning the validity of traditional “fundamentals” of the life sciences commercialization model for connecting brands with healthcare professionals, consumers, and economic … Read More »

Sales models are adapting to include new “channels”, such as tele-detailing, e-detailing, and web advertising to physicians. The primary channel to date has been live in-office interactions with sales representatives. What are needed are complementary secondary channels that … Read More »

Developing strategic partnerships to fill product markets and niches is a critical undertaking. An often overlooked opportunity lies in clinical and academic institutions, many who have robust early-stage research programs and a significant desire to collaborate with commerc … Read More »

Increases in clinical studies and protocol complexity are putting a strain on sites and their ability to recruit solely within their own walls. Competition for the patients has increased, while fewer patients in a practice are qualifying for contracted studies. Additive Pati … Read More »

This whitepaper provides an in-depth exploration of Brazil. It illustrates why Brazil's size, demographics, behaviors, and healthcare system make it the most intriguing market in Latin America.

This whitepaper discusses call center best practices.

This whitepaper discusses improving clinical trial efficiencies.

This whitepaper discusses Key Opinion Leaders and Influence Mapping studies.

India has substantial capacity to meet the rapidly growing demand for clinical trials. India has 300 universities, more than 750 graduate and post-graduate programs, and about 50 million college graduates. There are more than 700,000 medical professionals and over 600 ICH/GC … Read More »

In this Intelligence Report, CONTEXTWEB will address four key questions that pharma advertisers need to ask themselves in order to meet their campaign goals while maintaining compliance with federal regulations. How can I reach my target? Can I reach my target at scale? Can … Read More »

Learn how a clinical data gap analysis helps companies make the soundest decision with regard to planning for their products and using their precious resources most wisely.

The service industry needs to provide sponsor companies with more creative, innovative approaches and the experience and flexibility they demand. The new business model for providing this support is the functional service provider (FSP) model.

Proactive and comprehensive from strategic planning through execution, Supply Optimization enables sponsors to shorten development timelines and may even make it possible to bring drugs to market sooner – a win-win for pharmaceutical and biotechnology companies as well as … Read More »

This white paper will explore the challenges drug development executives face in maximizing the return of their drug pipeline and reveal the many benefits of networked drug development.

Are orphan drugs the next act for big pharma? It's beginning to look that way, based on big pharma's 70% market share in 2009 for rare and genetically inherited diseases, up from a little over 50% three years earlier.

This white paper shows how using Voice Biometrics can be used to securely and safely replace the lengthy paper-based signature processes with real-time voice signatures and the business benefits that can be gleaned.

This whitepaper discusses the importance of transportation budgets for clinical teams.

GLG conducted a survey of nearly 50 physicians across Asia-Pacific to find out their drug prescribing preferences and hospital/formulary influences when considering foreign original branded therapies compared with local generic therapies. Respondents represented opinions fro … Read More »

The paper will cover topic such as, targeting the right KOLs for specific roles, determining true KOL influence, allocating MSLs and sales-forces efficiently, and achieving the full benefit of hidden KOL value.

This white paper discusses the challenges of finding clinical trial patients.

This white paper discusses the benefits of an approved phrase library.

This white paper discusses the growth of the European market.

Check out the latest white paper from Snowfish.

This white paper discusses how to realize the potential of the CEE market.

This white paper discusses promoting patient-centered wellness.

This white paper discusses how to maximize the success of your CRO partnerships.

Explore trends and best practices for increasing planning efficiency in clinical development.

This whitepaper discusses the critical elements of CRM in rare disorder marketing.

For ePRO and patients around the world, it's a perfect storm of good news.

This white paper discussed the elements that are critical to the successful implementation of a patient adherence program on a global scale.

This white paper discusses how a strategic approach to comparator sourcing and risk management needs to consider supply chain as part of the solution.

This white paper discusses how the pathway to improved health care is through the patient-pharmacist interaction.

This white paper discusses the Top 10 MSL Training Considerations.

This white paper discusses the Mid-Level Practitioner Market and gives an overview of survey responses of practitioners in the field.